STOCK TITAN
  1. Home
  2. Sec-filings
  3. SPRB
  4. [4] – Parkman Healthcare Partners LLC (CIK 0001777015)

Spruce Biosciences insider filing shows 256-share buy, 1,050 held

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Spruce Biosciences (SPRB) — Form 4 insider trading update. Parkman Healthcare Partners LLC and Gregory Martinez reported trades on 10/06/2025 as indirect owners. They purchased 256 shares of common stock at a weighted average price of $17.9108 (within $17.55–$18.00), then sold 232 shares at $19.3264 (within $19.125–$19.63) and sold 25 shares at $17.4557 (within $17.44–$17.56). Following the reported transactions, they beneficially owned 1,050 shares indirectly through private funds. Each reporting person disclaims beneficial ownership beyond pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Parkman Healthcare Partners LLC, Martinez Gregory
Role 10% Owner | 10% Owner
Bought 256 shs ($5K)
Sold 257 shs ($5K)
Type Security Shares Price Value
Purchase Common Stock, $0.001 par value per share 256 $17.9108 $5K
Sale Common Stock, $0.001 par value per share 232 $19.3264 $4K
Sale Common Stock, $0.001 par value per share 25 $17.4557 $436.39
Holdings After Transaction: Common Stock, $0.001 par value per share — 1,050 shares (Indirect, See footnote)
Footnotes (4)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $17.55 to $18. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
  2. F2. The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $19.125 to $19.63. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $17.44 to $17.56. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did SPRB insiders report on Form 4?
Parkman Healthcare Partners LLC and Gregory Martinez reported indirect purchases and sales of SPRB common stock on 10/06/2025.

How many SPRB shares were bought and at what price?
They bought 256 shares at a weighted average price of $17.9108 within a range of $17.55–$18.00.

How many SPRB shares were sold and at what prices?
They sold 232 shares at a weighted average of $19.3264 (range $19.125–$19.63) and 25 shares at $17.4557 (range $17.44–$17.56).

What is the post-transaction indirect ownership for SPRB?
Following the reported transactions, the reporting persons indirectly beneficially owned 1,050 shares.

Were these holdings direct or indirect?
Indirect. The filing states the position is held through private funds, with beneficial ownership disclaimed beyond pecuniary interest.

Who are the reporting persons in this SPRB Form 4?
The form was filed by Parkman Healthcare Partners LLC and Gregory Martinez (Chief Investment Officer), as more than one reporting person.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Parkman Healthcare Partners LLC
(Last) (First) (Middle)
700 CANAL STREET
(Street)
STAMFORD CT 06902
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value per share 10/06/2025 P 256 A $17.9108(1) 1,307 I See footnote(2)
Common Stock, $0.001 par value per share 10/06/2025 S 232 D $19.3264(3) 1,075 I See footnote(2)
Common Stock, $0.001 par value per share 10/06/2025 S 25 D $17.4557(4) 1,050 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Parkman Healthcare Partners LLC
(Last) (First) (Middle)
700 CANAL STREET
(Street)
STAMFORD CT 06902
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Martinez Gregory
(Last) (First) (Middle)
700 CANAL STREET
(Street)
STAMFORD CT 06902
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $17.55 to $18. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
2. The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $19.125 to $19.63. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $17.44 to $17.56. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
As previously disclosed in Parkman Healthcare Partners LLC's Form 4 with respect to the Issuer filed on October 8, 2025, these securities are also indirectly beneficially owned by Gregory Martinez.
Parkman Healthcare Partners LLC, By: /s/ Gregory Martinez, Chief Investment Officer 10/15/2025
/s/ Gregory Martinez 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR